GLP-1 Drugs and Group Benefits: What Canadian Employers Need to Know in 2026
GLP-1 medications have become an increasingly important consideration in group benefits planning.
Originally associated primarily with diabetes treatment, some GLP-1 medications are also approved for weight management and other medical indications. Their growing use raises an important question for Canadian employers:
Should group benefits plans cover GLP-1 medications, and if so, how can that coverage be managed responsibly?
There is no single answer. Employers need to balance employee health needs, plan affordability, clinical eligibility, insurance requirements, and long-term financial sustainability.
GLP-1 Coverage Is Changing in Canada
The International Foundation of Employee Benefit Plans (IFEBP) reported in July 2026 that 37% of surveyed Canadian employers covered GLP-1 medications for both diabetes and weight loss. This was up from 31% in 2025 and 17% in 2024.
Meanwhile, 51% of surveyed employers covered GLP-1 medications for diabetes only. Another 12% reported coverage for other conditions, such as sleep apnea and cardiovascular disease. <Cite refs={["turn338921search0","turn338921search2"]}/>
These figures indicate that employer approaches are evolving, but coverage remains far from uniform.
For employers, the question is not simply whether GLP-1 medications should be covered. It is how coverage aligns with the company's benefits strategy, employee needs, and available budget.
Why GLP-1 Medications Matter to Employers
Prescription drug costs can have a meaningful impact on group benefits spending.
Some GLP-1 medications can involve substantial ongoing costs, depending on the medication, dosage, indication, and available coverage arrangements. Treatment duration and utilization can also affect the financial impact on a benefits plan.
This creates a planning challenge for employers.
A decision about coverage should consider more than the immediate prescription cost. Employers should also understand the potential impact on future utilization, the plan's financial sustainability, and the overall value of the coverage being provided.
At the same time, cost management should not be considered in isolation from appropriate access to medically indicated treatment.
Should Employers Cover GLP-1 Medications for Weight Management?
There is no universal answer. The appropriate approach depends on the employer's objectives, the insurance arrangement, and the coverage options available.
Before expanding coverage, employers should consider:
Employee health needs and access to treatment
Overall plan affordability
The specific medication and approved indication
Insurer eligibility and coverage requirements
Prior authorization and other utilization management rules
Expected utilization and treatment duration
Potential long-term costs
Employee expectations and communication
Employers should also distinguish between coverage for diabetes and coverage for weight management. A medication may be covered for one indication but excluded for another under a particular plan.
The objective is to make a considered decision based on the available evidence, plan rules, and financial implications rather than following a trend without evaluating its suitability.
How Can Employers Manage GLP-1 Coverage?
Depending on the insurer and plan design, employers may have several options for managing GLP-1 coverage.
1. Prior Authorization
Some plans require approval before a medication is covered.
Prior authorization can help confirm that the prescription meets the insurer's coverage requirements. The specific documentation and eligibility criteria vary by plan.
2. Clinical Eligibility Criteria
Coverage may depend on the medical indication, prescribing requirements, and other criteria established by the insurer.
Employers should understand these rules and how they affect access to treatment before making changes to their benefits package.
3. Step Therapy
Some plans use step therapy, which may require certain alternative treatments to be tried before coverage is approved for a particular medication.
Whether this approach is available or appropriate depends on the medication, clinical circumstances, and insurer requirements.
4. Health Care Spending Accounts
A Health Care Spending Account (HCSA) may be another option within an employer's broader benefits strategy.
However, eligibility for reimbursement depends on the account's structure, applicable Canada Revenue Agency requirements, and the expense in question. An HCSA should not be assumed to cover every GLP-1 medication or indication.
Employers should confirm the applicable rules with their benefits provider and tax advisor.
5. Employee Education
Employees should understand how their prescription drug coverage works, which eligibility requirements apply, and where to find information about their plan.
Clear communication can help set expectations and reduce confusion about covered medications, exclusions, and reimbursement requirements.
GLP-1 Coverage Is Part of a Broader Benefits Strategy
Prescription coverage is only one part of an employer's approach to supporting employee health.
Organizations may also consider access to nutritional counselling, physical activity resources, employee assistance programs, and appropriate healthcare support where these options align with their workforce needs.
These resources should complement, rather than replace, appropriate medical care or prescribed treatment.
The goal is to evaluate the benefits package as a whole and determine which combination of coverage and support best fits the organization.
What Should Employers Ask Their Benefits Broker?
Before making a decision about GLP-1 coverage, employers should ask their broker:
Does our current plan cover GLP-1 medications?
Which medications and medical indications are eligible?
What exclusions or clinical eligibility requirements apply?
Are prior authorization or step therapy requirements in place?
What utilization information is available for our plan?
Are any changes to the insurer's coverage rules expected?
How could expanded coverage affect our benefits costs?
What alternative plan designs or coverage arrangements are available?
Are there cost-management options that maintain appropriate access to treatment?
How should we communicate any coverage changes to employees?
These questions can help employers understand their current position and evaluate the available options before making changes.
The Bottom Line
GLP-1 coverage is becoming an increasingly relevant consideration for Canadian employers managing group benefits.
The decision should not be based solely on a medication's popularity or whether another employer covers it. Employers need to understand the clinical considerations, insurance requirements, potential costs, and implications for their overall benefits strategy.
Next Benefits helps Canadian employers review prescription drug coverage, understand potential cost pressures, and evaluate benefits options that balance employee needs with long-term affordability.
Contact Next Benefits to discuss your current group benefits plan and determine whether your prescription drug coverage remains appropriate for your business.
Sources
International Foundation of Employee Benefit Plans (IFEBP), GLP-1 Drug Trends: Canadian Employers Continue to Increase Coverage for Weight Loss, July 7, 2026.
Health Canada, Drug Product Database and approved product information for specific GLP-1 medications.
